107 related articles for article (PubMed ID: 19896313)
1. Inflammatory bowel disease and hepatitis B and C.
Chevaux JB; Bigard MA; Bensenane M; Oussalah A; Jarlot S; Belle A; Nani A; Bronowicki JP; Peyrin-Biroulet L
Gastroenterol Clin Biol; 2009 Dec; 33(12):1082-93. PubMed ID: 19896313
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
Chen D; Luo S; Ben Q; Lu L; Wan X; Wu J
Eur J Gastroenterol Hepatol; 2017 May; 29(5):509-515. PubMed ID: 28350740
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study.
Loras C; Saro C; Gonzalez-Huix F; Mínguez M; Merino O; Gisbert JP; Barrio J; Bernal A; Gutiérrez A; Piqueras M; Calvet X; Andreu M; Abad A; Ginard D; Bujanda L; Panés J; Torres M; Fernández-Bañares F; Viver JM; Esteve M;
Am J Gastroenterol; 2009 Jan; 104(1):57-63. PubMed ID: 19098850
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B and C viral infections screening in a Tunisian IBD population under immunosuppressive therapies.
Sabbah M; Yacoub H; Bellil N; Trad D; Ouakaa A; Elloumi H; Bbani N; Gargouri D
Rev Gastroenterol Peru; 2020; 40(3):246-251. PubMed ID: 33181811
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study.
Huang ML; Xu XT; Shen J; Qiao YQ; Dai ZH; Ran ZH
J Crohns Colitis; 2014 Apr; 8(4):282-7. PubMed ID: 24067604
[TBL] [Abstract][Full Text] [Related]
6. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease.
Gisbert JP; Chaparro M; Esteve M
Aliment Pharmacol Ther; 2011 Mar; 33(6):619-33. PubMed ID: 21416659
[TBL] [Abstract][Full Text] [Related]
7. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.
Degasperi E; Caprioli F; El Sherif O; Back D; Colombo M; Aghemo A
Expert Rev Gastroenterol Hepatol; 2016 Dec; 10(12):1373-1383. PubMed ID: 27718758
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature.
Katsanos KH; Tsianos VE; Zois CD; Zioga H; Vagias I; Zervou E; Christodoulou DK; Tsianos EV;
J Crohns Colitis; 2010 Oct; 4(4):450-65. PubMed ID: 21122543
[TBL] [Abstract][Full Text] [Related]
9. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).
Loras C; Gisbert JP; Saro MC; Piqueras M; Sánchez-Montes C; Barrio J; Ordás I; Montserrat A; Ferreiro R; Zabana Y; Chaparro M; Fernández-Bañares F; Esteve M;
J Crohns Colitis; 2014 Nov; 8(11):1529-38. PubMed ID: 25052345
[TBL] [Abstract][Full Text] [Related]
10. Performance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: results of the National Hepatitis Screening Survey. National Hepatitis Surveillance Group.
Kaur S; Rybicki L; Bacon BR; Gollan JL; Rustgi VK; Carey WD
Hepatology; 1996 Nov; 24(5):979-86. PubMed ID: 8903363
[TBL] [Abstract][Full Text] [Related]
11. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection.
Morisco F; Castiglione F; Rispo A; Stroffolini T; Sansone S; Vitale R; Guarino M; Biancone L; Caruso A; D'Inca R; Marmo R; Orlando A; Riegler G; Donnarumma L; Camera S; Zorzi F; Renna S; Bove V; Tontini G; Vecchi M; Caporaso N
J Viral Hepat; 2013 Mar; 20(3):200-8. PubMed ID: 23383659
[TBL] [Abstract][Full Text] [Related]
12. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases.
Belle A; Baumann C; Bigard MA; Zallot C; Gizard E; Guéant JL; Bronowicki JP; Peyrin-Biroulet L
Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):877-81. PubMed ID: 26121376
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab.
Moses J; Alkhouri N; Shannon A; Raig K; Lopez R; Danziger-Isakov L; Feldstein AE; Zein NN; Wyllie R; Carter-Kent C
Am J Gastroenterol; 2012 Jan; 107(1):133-8. PubMed ID: 21876562
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and risk factors of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus in multiply transfused recipients in Mexico.
Calderón GM; González-Velázquez F; González-Bonilla CR; Novelo-Garza B; Terrazas JJ; Martínez-Rodríguez ML; Cortés-Márquez SR; Blanco-Flores JP; Rodríguez-Rodríguez A; Del Campo MA; Cortés-Gómez R; Mejía-Bocanegra MG
Transfusion; 2009 Oct; 49(10):2200-7. PubMed ID: 19538543
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B and C virus prevalence and related factors in patients with inflammatory bowel diseases.
Yakut M; Kabaçam G; Üstün Y; Cetinkaya H; Soykan I
Clin Res Hepatol Gastroenterol; 2011 Dec; 35(12):857. PubMed ID: 21963993
[No Abstract] [Full Text] [Related]
16. Factors for hepatitis B vaccination and abnormal liver function in Chinese patients with inflammatory bowel disease: a single center experience.
Leung WK; Liu KSh; Seto WK; Chan KH; Tong T; Yuen MF; Lai CL; Hung IF
J Dig Dis; 2013 Nov; 14(11):596-603. PubMed ID: 23870196
[TBL] [Abstract][Full Text] [Related]
17. [Does long-term erythropoietin therapy influence the prevalence of serum markers of hepatitis B and C in haemodialysed uraemic patients?].
Mesjasz J; Wiecek A; Gonciarz Z; Mazur W; Kokot F
Pol Merkur Lekarski; 2004 Apr; 16(94):362-7. PubMed ID: 15517934
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients.
Yakaryilmaz F; Gurbuz OA; Guliter S; Mert A; Songur Y; Karakan T; Keles H
Ren Fail; 2006; 28(8):729-35. PubMed ID: 17162434
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.
Papa A; Felice C; Marzo M; Andrisani G; Armuzzi A; Covino M; Mocci G; Pugliese D; De Vitis I; Gasbarrini A; Rapaccini GL; Guidi L
J Crohns Colitis; 2013 Mar; 7(2):113-9. PubMed ID: 22464811
[TBL] [Abstract][Full Text] [Related]
20. HBV and HCV infection in Japanese dental care workers.
Nagao Y; Matsuoka H; Kawaguchi T; Ide T; Sata M
Int J Mol Med; 2008 Jun; 21(6):791-9. PubMed ID: 18506374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
